-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5
Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5
Nicosia, Cyprus, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019. Specifically, Kraspharma went from $5,563,056 (USD) at the end of 2019 to $17,853,905 at the end of 2020. The growth was featured in the ratings by the authoritative Russian industry publication "Remedium", published in Q3 of 2021.
(See https://remedium.ru/industry/pharmindustry/analysis/Reyting-predpriyatiy-farmpromyshlennosti-po-obemu-valovoy-pribyli-za-2020-god/)
Remedium's ratings are calculated based on the annual financial statements of 90 companies representing the largest pharmaceutical companies in the country. Remedium's ratings only include profitable businesses. According to these standards, PJSC Kraspharma entered the top five largest companies in terms of gross profit growth dynamics, outpacing the long-term leaders of this rating by ten times. The company also entered the TOP-30 of the largest pharmaceutical companies in terms of gross profit, retaining its position since 2019.
Also, according to the monthly monitoring of the Russian pharmaceutical market compiled by DSM Group, for the first nine months of 2020 PJSC Kraspharma entered the TOP-5 rating of manufacturers of antibacterial agents for systemic use. During the reporting period, PJSC Kraspharma increased the volume of sold antibiotics by more than 40%. For more details see:
https://cyberleninka.ru/article/n/obzor-prodazh-antibakterialnyh-preparatov-po-itogam-9-mesyatsev-2020-goda/viewer
https://www.kommersant.ru/doc/4626162
https://www.elibrary.ru/title_about_new.asp?id=9038
Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate," or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
Nicosia, Cyprus, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019. Specifically, Kraspharma went from $5,563,056 (USD) at the end of 2019 to $17,853,905 at the end of 2020. The growth was featured in the ratings by the authoritative Russian industry publication "Remedium", published in Q3 of 2021.
塞浦路斯尼科西亞,2021年11月19日(環球通訊社)拉法爾瑪製藥公司(Rafarma PharmPharmticals,Inc.) 場外交易:(拉法)據報道,PJSC KrasPharma在2020年底進入了2020年俄羅斯最具活力和最大的製藥公司前5名,顯示出令人難以置信的增長速度,與2019年相比淨利潤增長了220.9%。具體地説,KrasPharma從2019年底的5563,056美元升至2020年底的17,853,905美元。這一增長在2021年第三季度出版的俄羅斯權威行業出版物“補救”(Remedium)的評級中有所體現。
(See https://remedium.ru/industry/pharmindustry/analysis/Reyting-predpriyatiy-farmpromyshlennosti-po-obemu-valovoy-pribyli-za-2020-god/)
(請參閲https://remedium.ru/industry/pharmindustry/analysis/Reyting-predpriyatiy-farmpromyshlennosti-po-obemu-valovoy-pribyli-za-2020-god/)
Remedium's ratings are calculated based on the annual financial statements of 90 companies representing the largest pharmaceutical companies in the country. Remedium's ratings only include profitable businesses. According to these standards, PJSC Kraspharma entered the top five largest companies in terms of gross profit growth dynamics, outpacing the long-term leaders of this rating by ten times. The company also entered the TOP-30 of the largest pharmaceutical companies in terms of gross profit, retaining its position since 2019.
Remedium的評級是根據代表美國最大製藥公司的90家公司的年度財務報表計算得出的。Remedium的評級只包括盈利業務。根據這些標準,PJSC KrasPharma進入了毛利增長動力最大的前五家公司,超過了這一評級的長期領先者十倍。該公司還進入了毛利潤最大的30家制藥公司之列,自2019年以來一直保持着這一地位。
Also, according to the monthly monitoring of the Russian pharmaceutical market compiled by DSM Group, for the first nine months of 2020 PJSC Kraspharma entered the TOP-5 rating of manufacturers of antibacterial agents for systemic use. During the reporting period, PJSC Kraspharma increased the volume of sold antibiotics by more than 40%. For more details see:
此外,根據帝斯曼集團(DSM Group)編制的俄羅斯藥品市場月度監測,2020年前9個月,PJSC KrasPharma進入了全身使用抗菌劑製造商的前5名。在本報告所述期間,PJSC KrasPharma將抗生素的銷售量增加了40%以上。有關更多詳細信息,請參閲:
https://cyberleninka.ru/article/n/obzor-prodazh-antibakterialnyh-preparatov-po-itogam-9-mesyatsev-2020-goda/viewer
https://www.kommersant.ru/doc/4626162
https://www.elibrary.ru/title_about_new.asp?id=9038
Https://cyberleninka.ru/article/n/obzor-prodazh-antibakterialnyh-preparatov-po-itogam-9-mesyatsev-2020-goda/viewer
Https://www.kommersant.ru/doc/4626162
Https://www.elibrary.ru/title_about_new.asp?id=9038
Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate," or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
前瞻性陳述:本新聞稿包含1934年證券交易法第21E節所指的“前瞻性陳述”。除本文包含的歷史事項外,本新聞稿中的陳述均為前瞻性陳述。在不限制前述一般性的情況下,諸如“可能”、“將”、“到”、“計劃”、“預期”、“相信”、“預期”、“打算”、“可能”、“將”、“估計”或“繼續”等詞語或其負面的其他變體或類似術語旨在識別前瞻性陳述。前瞻性陳述涉及已知和未知的風險、不確定因素和其他因素,這些風險、不確定性和其他因素可能導致我們的實際結果、表現或成就與前瞻性陳述明示或暗示的任何未來結果、表現或成就大不相同。此外,前瞻性陳述僅代表我們管理層截至本文發佈之日的信念和假設。有關可能導致實際結果與這些前瞻性陳述大不相同的因素的更多信息,請參閲公司向場外交易市場提交的文件。除非法律要求,否則我們沒有義務公開更新這些前瞻性陳述,或更新實際結果可能與這些前瞻性陳述中預期的結果大不相同的原因,即使未來有新的信息。
For more information contact:
RAFARMA
(307) 429-2029
如需更多信息,請聯繫:
拉法爾馬
(307) 429-2029
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧